Fig. 9From: Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastomaAZ + MS-275 decreased the in vivo tumorigenic potential of pretreated NB SH-SY5Y cells. a presents the in vivo serial heterotransplantation study (x20 and x40) with pretreated NB xenograft cells showing the morphology, b H&E histology, c volume and d weight after 37 days treatment with AZ + MS-275 compared to untreated group in SH-SY5Y xenografts. Notably, AZ + MS-275 caused a significant reduction in tumor volumes (69 ± 0.84%; p = 0.0002) and weights (81 ± 0.78%; p = 0.0001) after 37 days compared to xenografts generated from untreated cellsBack to article page